BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. INZY (“the Firm” or “Inozyme”), a clinical-stage biopharmaceutical firm growing modern therapeutics for uncommon ailments that have an effect on bone well being and blood vessel perform, at this time introduced that Matt Winton, Ph.D., Senior Vice President and Chief Working Officer of Inozyme, will take part in a hearth chat on the Piper Sandler thirty sixth Annual Healthcare Convention on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
A dwell webcast of the hearth chat will be accessed from the Investor Relations part of Inozyme’s web site underneath events, the place a replay of the occasion may even be accessible for a restricted time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical firm devoted to growing modern therapeutics for uncommon ailments that have an effect on bone well being and blood vessel perform. We’re consultants within the PPi-Adenosine Pathway, the place the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of clean muscle cells inside blood vessels). Disruptions on this pathway affect the degrees of those molecules, resulting in extreme musculoskeletal, cardiovascular, and neurological situations, together with ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme substitute remedy (ERT) designed to extend PPi and adenosine, enabling the potential remedy of a number of ailments brought on by deficiencies in these molecules. It’s at present in scientific improvement for the remedy of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By concentrating on the PPi-Adenosine Pathway, INZ-701 goals to appropriate pathological mineralization and intimal proliferation, addressing the numerous morbidity and mortality in these devastating ailments.
For extra info, please go to https://www.inozyme.com/ or observe Inozyme on LinkedIn, X, and Facebook.
Contacts
Traders:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Company Communications
(617) 461-2442
[email protected]
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
[email protected]
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
